Bay Rivers Group Lowers Position in iShares Biotechnology ETF (NASDAQ:IBB)

Bay Rivers Group decreased its position in iShares Biotechnology ETF (NASDAQ:IBB) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,365 shares of the financial services provider’s stock after selling 84 shares during the quarter. Bay Rivers Group’s holdings in iShares Biotechnology ETF were worth $313,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hsbc Holdings PLC lifted its position in iShares Biotechnology ETF by 47.1% during the 2nd quarter. Hsbc Holdings PLC now owns 3,670 shares of the financial services provider’s stock valued at $504,000 after acquiring an additional 1,175 shares during the period. Bank of Montreal Can grew its stake in shares of iShares Biotechnology ETF by 2.6% in the second quarter. Bank of Montreal Can now owns 36,198 shares of the financial services provider’s stock worth $5,086,000 after acquiring an additional 920 shares during the period. Creative Planning raised its stake in iShares Biotechnology ETF by 2.9% during the 2nd quarter. Creative Planning now owns 67,902 shares of the financial services provider’s stock valued at $9,320,000 after buying an additional 1,905 shares during the last quarter. NewEdge Advisors LLC increased its position in iShares Biotechnology ETF by 20.1% during the second quarter. NewEdge Advisors LLC now owns 11,633 shares of the financial services provider’s stock valued at $1,597,000 after acquiring an additional 1,944 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. increased its position in shares of iShares Biotechnology ETF by 2.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 11,722 shares of the financial services provider’s stock valued at $1,609,000 after purchasing an additional 229 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $138.37 on Tuesday. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57. The firm has a 50 day moving average of $136.15 and a 200 day moving average of $141.77.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.